✨ Free AI Report
Freenome, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Freenome, Inc.
Company Research

Freenome, Inc.: Business Overview, Financials & Competitive Analysis

Freenome, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Well-funded AI biotech company with validated blood-based cancer detection technology approaching commercialization and public markets transition. Freenome demonstrates strong market fundamentals with validated clinical data, substantial institutional backing ($240M PIPE funding), and strategic partnerships with major companies. The imminent IPO and 2026 product launches position it well, though pre-revenue status.

What is Freenome, Inc.'s industry? Freenome, Inc. (freenome.com) operates in Biotechnology - Early Cancer Detection. AskCyborg classifies Freenome, Inc. under Biotechnology - Early Cancer Detection in its company registry.

Freenome develops blood-based screening tests that combine multiple biological signals with artificial intelligence to detect cancer in early stages. The company is expected to go public via SPAC merger in the first h...

8/ 10Strong

Cyborg Score thesis

Well-funded AI biotech company with validated blood-based cancer detection technology approaching commercialization and public...

Read the full analyst-debate transcript →
Industry Biotechnology - Early Cancer Detection
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest Freenome, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Freenome, Inc.

AskCyborg analysts argue the bull and bear cases for Freenome, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Freenome, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Freenome, Inc. Overview

Pro stress-test →

Freenome develops blood-based screening tests that combine multiple biological signals with artificial intelligence to detect cancer in early stages. The company is expected to go public via SPAC merger in the first half of 2026, listing on Nasdaq under ticker FRNM with an anticipated post-transaction equity value of approximately $1.1 billion.

Strategic Profile

Pro stress-test →

Freenome's technology has been clinically validated through its pivotal PREEMPT CRC study and recent JAMA manuscript, with expected launch of multiple tests in 2026. The company has secured strategic partnerships including collaborations with Roche for international commercialization and with NVIDIA Healthcare to leverage advanced AI for cancer detection analysis.

Competitive Landscape

Pro stress-test →

Freenome competes in the rapidly growing blood-based cancer screening market against companies like Grail (Illumina subsidiary), Exact Sciences, and others. The company differentiates through its AI/ML-enabled multiomics platform and partnerships with major healthcare and technology companies. Early clinical validation and expected 2026 launches position it competitively, though the space remains crowded with well-funded competitors.

Industry Context

Freenome, Inc. operates in Biotechnology - Early Cancer Detection.

Key facts

Founded: Not available · Headquarters: Brisbane, US · Employees: 392 · Market cap: $1.1B (post-SPAC equity value)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Freenome, Inc..

  • SPAC merger expected in H1 2026 with $330M total capital raising and $1.1B valuation provides runway for commercialization phase
  • Multiple product launches planned for 2026 across different cancer types signal progression toward revenue generation
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Business combination agreement with Perceptive Capital Solutions Corp (NASDAQ: PCSC) announced; expected to close H1 2026 with $240M PIPE investment led by Perceptive Advisors and RA Capital
  • 2025Strategic collaboration with NVIDIA Healthcare announced to leverage advanced AI for biological signal analysis
  • +2 moreTrack every material event for Freenome, Inc. as it happens. Explore monitoring →
Get alerted when Freenome, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

GalleriMulti-cancer detection blood test→ShieldPlasma-based colorectal cancer screening→iChor MedicalLiquid biopsy cancer detection platform→

Compare Freenome, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Freenome, Inc. operates in Biotechnology - Early Cancer Detection. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Early Cancer Detection research →
NEW · MCP server

Ask your AI assistant about Freenome, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Freenome, Inc. and its top competitor on Cyborg Score”
“What did Freenome, Inc. do this quarter?”
“Is Freenome, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Freenome, Inc. do?+
Freenome develops blood-based screening tests that combine multiple biological signals with artificial intelligence to detect cancer in early stages. The company is expected to go public via SPAC merger in the first h...
What is Freenome, Inc.'s Cyborg Score?+
Freenome, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Freenome, Inc.'s main competitors?+
Named competitors include Galleri, Shield, iChor Medical. The full competitive landscape is in the AskCyborg report.
How can I get the full Freenome, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Freenome, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Freenome, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.